Rifampicin increases the levels of the active
metabolite of
leflunomide (A771726) by 40%.
There would seem to be no reason for avoiding concurrent use, but the manufacturers advise caution as levels may build up over time. It may be prudent to increase the frequency of
leflunomide monitoring if these two drugs are used together.